$AQST

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards

Aquestive Therapeutics (AQST) reported Q2 2026 results, staying on track to resubmit Anaphylm epinephrine film to the FDA in Q3 2026. Studies addressed FDA concerns, with improved packaging and labeling. Revenue rose 38% to $13.8M, but net loss widened to $22.9M. Cash reserves stand at $98.5M. The company also advanced its epinephrine prodrug platform and manufacturing business.

Aquestive (AQST) reported progress in its Anaphylm resubmission to the FDA, addressing previous issues with packaging and administration. The company's recent studies showed significant improvements in ease of use and effectiveness. Aquestive aims to resubmit Anaphylm before the end of the quarter and believes the product has a strong market opportunity, potentially exceeding $1 billion annually, due to its clinical differentiation and ease of use.

Aquestive Therapeutics (NASDAQ:AQST) reported Q2 revenue of $13.8M, up 38% year over year, and a net loss of $22.9M ($0.18/share). Excluding a $11.7M debt-extinguishment loss, net loss was $11.2M. The company discussed FDA resubmission review timing for Anaphylm, cash of $98.5M, and maintained 2026 guidance of $46M to $50M revenue.

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • Successfully completed human factors validation study and pharmacokinetic study for Anaphylm™ (dibutepinephrine) sublingual film • Remains on track to resubmit Anaphyl

Aquestive Therapeutics (AQST) shares rose about 9.4% pre-open after the company reported positive topline results from two pivotal studies for its Anaphylm (dibutepinephrine) sublingual film. The data address FDA concerns from a January 2026 Complete Response Letter and the company said its NDA resubmission remains on track for Q3 2026.

Aquestive Therapeutics (AQST) reported positive human factors and PK topline results for Anaphylm, including faster median pouch open time (17s to 3s) and fewer opening and placement errors. PK Cmax was comparable vs clinician dosing (391.7 vs 357.6 pg/mL) with median Tmax 12 min. No serious adverse events were reported. Aquestive plans to resubmit the NDA in Q3 2026.

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. aqst-20260610 0001398733 false 0001398733 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): J

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.

Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) on behalf of investors who purchased securities between June 16, 2025, and January 8, 2026. The lawsuit alleges that Aquestive gave the false impression that its New Drug Application for Anaphylm would be approved by the January 31, 2026 PDUFA date, despite the FDA identifying deficiencies. Investors who suffered losses have until May 4, 2026, to apply to be appointed as lead plaintiff.